# MBX Biosciences Inc. (MBX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $61.72, market value $3.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). MBX Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 7.2×**. The shares trade at 7.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.9%** (5-yr avg -17.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -23.6%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 59.1%**. Earnings per share rose 59.1%.

## Financial health
- **Current ratio: 24.62** (quick 24.62). Current assets cover the next year's liabilities 24.62 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. MBX Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover MBX Biosciences Inc.; the consensus is strong_buy, with an average price target of $88.36 (+43% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 377.7%** (YTD 95.7%, 3-mo 103.8%). The shares are up 377.7% over twelve months including dividends.
- **From 52-week high: -15.0%** (540.9% above the low). Trading 15% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 44**. An RSI of 44 is neutral.
- **Beta (1 yr): 1.48** (volatility 130%). Beta of 1.48 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MBX · Page: https://foliofundamentals.com/stocks/mbx

Not investment advice.